All Oncology News

Ferdinandos Skoulidis, MD, PhD, discusses the necessity for targeting and screening patients for KRAS G12C mutations.

Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.

Karen L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

The FDA has granted a fast track designation to eryaspase for use as a potential therapeutic option in patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.

Zanubrutinib resulted in a significant improvement in progression-free survival per independent review committee assessment vs bendamustine plus rituximab in treatment-naïve patients with chronic lymphocytic leukemia whose tumors did not exhibit the deletion of chromosome 17p13.1.

The European Commission has approved nivolumab for use as an adjuvant treatment in adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after neoadjuvant chemoradiation.

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.

The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma, has indicated that the doublet resulted in an increased risk of death in this population.

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program.

Chordoma is described as an extremely rare sarcoma that attacks the bones of the spine and base of the skull.

The IDH2 inhibitor enasidenib demonstrated promising efficacy in combination with azacitidine and as a single agent in patients with high-risk, IDH2-mutated myelodysplastic syndrome.

Milind Javle, MD, discusses the potential impact of infigratinib on the treatment landscape of FGFR2 fusion–positive cholangiocarcinoma.

Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.

Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.

Novel combinations with agents, such as pevonedistat, eprenetapopt, venetoclax or magrolimab, plus hypomethylating agents like azacitidine are being evaluated to determine whether they can improve upon the lackluster median survival for patients with higher-risk myelodysplastic syndrome.